NASDAQ:NTRANatera Stock Price, Forecast & News

$45.47

-0.03 (-0.07 %)

(As of 05/25/2020 10:53 AM ET)

Add

Compare

Today's Range

$44.87

Now: $45.47▼

$46.42

50-Day Range

$26.36

MA: $36.80▼

$46.95

52-Week Range

$16.87

Now: $45.47▼

$49.22

Volume417,580 shs

Average Volume972,256 shs

Market Capitalization$3.58 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.33

Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Evercord, a cord blood and cord tissue processing and storage service; and Signatera, a circulating tumor DNA technology that analyzes and tracks mutations to an individual's tumor. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners in the United States and internationally. Natera, Inc. has research collaborations with the Institut Jules Bordet and Fox Chase Cancer Center. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.

Beat the Market (BTM) Rank^™

2.4 Analyst's Opinion

Consensus Rating
Natera has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $45.13, Natera has a potential downside of 0.8% from its current price of $45.47.
Amount of Analyst Coverage
Natera has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.7 Community Rank

Outperform Votes
Natera has received 356 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Natera has received 310 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Natera has received 53.45% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Natera and other stocks. Vote “Outperform” if you believe NTRA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NTRA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Natera does not currently pay a dividend.
Dividend Growth
Natera does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,251,066.00 in company stock.
Percentage Held by Insiders
Only 9.29% of the stock of Natera is held by insiders.
Percentage Held by Institutions
93.91% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Natera are expected to grow in the coming year, from ($2.15) to ($1.77) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Natera is -26.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Natera is -26.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Natera has a P/B Ratio of 12.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.35 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Medical laboratories

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:NTRA

Previous Symbol

CUSIPN/A

CIK1604821

Webwww.natera.com

Phone650-249-9090

Debt

Debt-to-Equity Ratio0.38

Current Ratio2.81

Quick Ratio2.73

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$302.33 million

Price / Sales11.84

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.59 per share

Price / Book12.67

Profitability

EPS (Most Recent Fiscal Year)($1.99)

Net Income$-124,830,000.00

Net Margins-38.28%

Return on Equity-78.56%

Return on Assets-29.51%

Miscellaneous

Employees1,039

Outstanding Shares78,720,000

Market Cap$3.58 billion

Next Earnings Date8/5/2020 (Estimated)

OptionableOptionable

Receive NTRA News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter.

Natera (NASDAQ:NTRA) Frequently Asked Questions

How has Natera's stock been impacted by COVID-19 (Coronavirus)?

Natera's stock was trading at $31.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NTRA stock has increased by 46.6% and is now trading at $45.47. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Natera?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Natera.

When is Natera's next earnings date?

Natera is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Natera.

How were Natera's earnings last quarter?

Natera Inc (NASDAQ:NTRA) released its quarterly earnings results on Wednesday, May, 6th. The medical research company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.12. The medical research company earned $94.01 million during the quarter, compared to the consensus estimate of $85.02 million. Natera had a negative net margin of 38.28% and a negative return on equity of 78.56%. The firm's revenue for the quarter was up 40.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.54) EPS. View Natera's earnings history.

What guidance has Natera issued on next quarter's earnings?

Natera issued an update on its first quarter 2020 Pre-Market earnings guidance on Monday, April, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $89-91 million, compared to the consensus revenue estimate of $79.45 million.

What price target have analysts set for NTRA?

8 brokerages have issued 12 month price objectives for Natera's shares. Their forecasts range from $36.00 to $56.00. On average, they anticipate Natera's share price to reach $45.13 in the next twelve months. This suggests that the stock has a possible downside of 0.8%. View analysts' price targets for Natera.

What are Wall Street analysts saying about Natera stock?

Here are some recent quotes from research analysts about Natera stock:

1. According to Zacks Investment Research, "Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. " (5/12/2020)
2. Canaccord Genuity analysts commented, "We recently had the privilege of hosting Natera CEO Steve Chapman and CFO a well-attended fireside chat at the 39th in Boston. We continue to view NTRA as an undervalued cancer company trading at the multiple of an NIPT company. NTRA remains one of our favorite stocks and is one of our top picks for 2019. We reiterate our BUY rating and $38 PT. Signatera may be a game-changer in recurrence monitoring and MRD." (9/11/2019)

Has Natera been receiving favorable news coverage?

Media coverage about NTRA stock has been trending somewhat positive on Monday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Natera earned a news sentiment score of 1.5 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutNatera.

Who are some of Natera's key competitors?

Some companies that are related to Natera include Guardant Health (GH), ELEKTA AB/ADR (EKTAY), InVitae (NVTA), CareDx (CDNA), Veracyte (VCYT), RadNet (RDNT), Castle Biosciences (CSTL), Personalis (PSNL), Centogene (CNTG), Fulgent Genetics (FLGT), DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Anpac Bio-Medical Science (ANPC) and Biocept (BIOC). View all competitors.

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Athabasca Oil (ATH), Chipotle Mexican Grill (CMG), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

Who are Natera's key executives?

Natera's management team includes the following people:

Dr. Matthew Rabinowitz, Co-Founder & Exec. Chairman (Age 46)
Mr. Steve Chapman, CEO, Pres & Director (Age 40)
Mr. Michael Brophy, Chief Financial Officer (Age 39)
Mr. Jonathan Sheena, Co-Founder, Chief Technology Officer & Director (Age 46)
Mr. Robert A. Schueren, Chief Operating Officer (Age 57)

When did Natera IPO?

(NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Who are Natera's major shareholders?

Natera's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.10%), Orbimed Advisors LLC (4.25%), Fred Alger Management LLC (4.19%), Wells Fargo & Company MN (3.74%), JPMorgan Chase & Co. (3.66%) and State Street Corp (3.23%). Company insiders that own Natera stock include Gail Boxer Marcus, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren and Steven Leonard Chapman. View institutional ownership trends for Natera.

Which institutional investors are selling Natera stock?

NTRA stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Invesco Ltd., Fred Alger Management LLC, Federated Hermes Inc., Morgan Stanley, Nuveen Asset Management LLC, Jennison Associates LLC, and BlackRock Inc.. Company insiders that have sold Natera company stock in the last year include Gail Boxer Marcus, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren, and Steven Leonard Chapman. View insider buying and selling activity for Natera.

Which institutional investors are buying Natera stock?

NTRA stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Orbimed Advisors LLC, Wells Fargo & Company MN, Loomis Sayles & Co. L P, Driehaus Capital Management LLC, Two Sigma Advisers LP, Castleark Management LLC, and Balyasny Asset Management LLC. View insider buying and selling activity for Natera.

How do I buy shares of Natera?

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $45.47.

How big of a company is Natera?

Natera has a market capitalization of $3.58 billion and generates $302.33 million in revenue each year. The medical research company earns $-124,830,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Natera employs 1,039 workers across the globe.

What is Natera's official website?

The official website for Natera is www.natera.com.

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff